investig
method
identifi
specif
cyclophilin
cypd
inhibitor
deriv
quinoxalin
thu
develop
possibl
lead
compound
inhibit
mitochondri
permeabl
transit
mpt
pore
open
method
kinet
analysi
cypdinhibitor
interact
quantit
perform
use
surfac
plasmon
reson
spr
fluoresc
titrat
ft
techniqu
ic
valu
inhibitor
determin
ppias
inhibit
activ
assay
result
equilibrium
dissoci
constant
k
seven
compound
bind
cypd
ic
valu
consist
spr
ft
result
compound
high
inhibit
activ
ca
depend
rat
liver
mitochondri
swell
ca
uptakereleas
compound
bind
select
cypd
cypa
conclus
agreement
measur
ic
valu
result
spr
ft
suggest
method
appropri
power
method
identifi
cypd
inhibitor
compound
screen
use
method
reason
cypd
inhibitor
potent
abil
inhibit
mitochondri
swell
bind
select
indic
could
potenti
use
inhibit
mpt
pore
open
apoptosi
essenti
normal
develop
age
multicellular
organ
abnorm
regul
apoptosi
result
multipl
human
diseas
mitochondria
releas
apoptogen
protein
cytochrom
c
apoptosisinduc
factor
aif
cytosol
involv
signal
pathway
caspas
induc
cell
apoptosi
one
major
pathway
releas
apoptogen
factor
cytosol
via
ruptur
outer
mitochondri
membran
due
mitochondri
permeabl
transit
mpt
pore
open
suggest
mpt
pore
play
potent
role
cell
age
open
mpt
pore
may
caus
chang
mitochondri
shape
function
massiv
swell
mitochondria
ruptur
outer
membran
releas
intermembran
compon
induc
apoptosi
report
agent
inhibit
mpt
may
therapeut
potenti
treatment
human
diseas
ischemiareperfus
injuri
peripher
organ
trauma
neurodegen
diseas
recent
studi
shown
mpt
pore
compos
three
major
protein
voltagedepend
anion
channel
vdac
outer
membran
form
larg
h
ofil
pore
diamet
nm
adenin
nucleotid
transloc
ant
mediat
adpatp
exchang
inner
membran
cyclophilin
cypd
cypd
belong
famili
highli
homolog
peptidyl
prolyl
cistran
isomeras
ppias
thought
import
protein
fold
bind
immunosuppressor
cyclosporin
csa
known
cypd
mitochondrialtarget
ppias
even
though
specif
physiolog
role
larg
obscur
cypd
confirm
play
decis
role
mpt
pore
regul
ppias
activ
cypd
might
necessari
step
mpt
pore
open
model
recent
propos
concern
mechan
permeabl
transitionrel
cytochrom
c
releas
wherebi
ca
requir
induct
mpt
pore
open
might
due
ca
depend
interact
cypd
ant
report
cypd
inhibitor
csa
analogu
may
block
mpt
pore
open
therebi
make
discov
cypd
inhibitor
appeal
project
howev
knowledg
investig
small
molecular
cypdspecif
inhibitor
allow
brain
penetr
still
challeng
paper
report
novel
quinoxalin
deriv
scheme
figur
inhibit
ppias
activ
cypd
use
surfac
plasmon
reson
spr
fluoresc
titrat
techniqu
kinet
cypdinhibitor
interact
investig
compound
inhibit
effect
rat
liver
ca
deped
mitochondri
swell
ca
uptakereleas
also
determin
bind
select
cypd
cypa
test
compound
analyz
explain
base
molecular
dock
techniqu
hope
research
provid
use
approach
discoveri
cyclophilin
inhibitor
thu
help
develop
promis
compound
use
cypd
drug
target
inhibit
mpt
pore
open
solvent
reagent
purchas
commerci
use
without
purif
h
nuclear
magschem
gener
synthet
procedur
seven
test
compound
netic
reson
nmr
spectra
mhz
record
varian
palo
alto
california
usa
spectromet
plasmid
extract
perform
use
genelut
plasmid
miniprep
kit
sigmaaldrich
st
loui
missouri
usa
compound
quinoxalin
synthes
accord
patent
method
r
ethyl
nipecot
ethyl
nipecot
prepar
accord
previous
publish
method
gener
prepar
procedur
compound
chemic
structur
seven
test
compound
shown
figur
gener
synthet
procedur
shown
scheme
briefli
compound
prepar
five
step
quinoxalin
solut
quinoxalin
mg
mmol
triethylamin
mmol
dichloromethan
ml
ad
triphosgen
mg
mmol
stir
mixtur
stir
room
temperatur
h
ethanol
mmol
ad
anoth
h
stir
solvent
evapor
vacuum
give
crude
product
purifi
flash
column
chromatographi
silica
gel
use
petroetherethyl
acet
eluent
obtain
compound
mg
yield
yellowish
amorph
solid
n
ndiethylcarbamoyl
amino
quinoxalin
synthes
use
method
similar
describ
prepar
except
diethylamin
use
instead
ethanol
brown
amorph
solid
mg
yield
quinoxalin
prepar
use
method
similar
describ
prepar
except
morpholin
use
instead
ethanol
yellow
amorph
solid
mg
yield
n
ndiisopropylcarbamoyl
amino
quinoxalin
prepar
use
method
similar
describ
prepar
except
diisopropylamin
use
instead
ethanol
brown
amorph
solid
mg
yield
prepar
histag
human
cypa
protein
clone
techniqu
includ
polymeras
chain
reaction
pcr
restrict
ligat
e
coli
transform
plasmid
dna
prepar
carri
accord
standard
method
histag
cypa
protein
express
purifi
plasmid
accord
publish
procedur
prepar
rat
cypd
protein
plasmid
zeocypd
kindli
provid
dr
jame
lechleit
univers
texa
health
scienc
center
use
forward
primer
contain
ecori
site
revers
primer
contain
xhoi
site
pcr
product
subclon
vector
ecori
xhoi
site
obtain
express
plasmid
sequenc
carri
confirm
insert
e
coli
strain
prepar
luriabertani
medium
contain
mgml
ampicillin
bacteria
transform
grown
od
reach
iptg
ad
final
concentr
mmoll
induc
gstcypd
express
c
overnight
bacteria
harvest
lyse
sonic
sonic
buffer
salin
pb
mmoll
phenylmethylsulfonyl
fluorid
pmsf
ph
mmoll
ethylenediamin
tetraacet
acid
edta
triton
bacteri
lysat
centrifug
supernat
collect
gstcypd
protein
purifi
use
glutathion
sepharos
column
amersham
bioscienc
uppsala
sweden
purifi
cypd
protein
obtain
oncolumn
cleavag
gstcypd
use
thrombin
accord
instruct
given
manufactur
glutathion
sepharos
column
amersham
bioscienc
puriti
obtain
cypd
protein
verifi
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
singl
band
surfac
plasmon
reson
technologybas
biacor
analys
interact
compound
cypd
perform
use
dual
flow
cell
biacor
instrument
biacor
ab
uppsala
sweden
experi
carri
use
hbsep
mmoll
acid
hepe
mmoll
nacl
mmoll
edta
surfact
ph
run
buffer
constant
flow
rate
protein
immobil
directli
coval
hydrophil
carboxymethyl
dextran
matrix
sensor
chip
biacor
use
standard
primari
amin
coupl
reaction
protein
bound
sensor
chip
dilut
mmoll
sodium
acet
buffer
ph
concentr
concentr
compound
dissolv
run
buffer
vari
data
analys
carri
use
biaevalu
softwar
sensorgram
process
automat
correct
nonspecif
bulk
refract
index
effect
kinet
analys
ligand
bind
protein
perform
base
langmuir
bind
fit
model
accord
procedur
describ
softwar
manual
fluoresc
titrat
assay
fluoresc
measur
perform
hitachi
tokyo
japan
fluoresc
spectrophotomet
equip
thermal
control
chang
intrins
tryptophan
fluoresc
compound
bound
protein
cypa
cypd
monitor
use
procedur
similar
describ
literatur
experi
carri
pb
ph
protein
concentr
set
compound
concentr
vari
compound
prepar
dimethylsulfoxid
stock
solut
mmoll
fluoresc
absorpt
record
excit
nm
emiss
nm
ppias
inhibit
activ
assay
ppias
activ
assay
protein
cypa
cypd
perform
base
publish
method
modif
substrat
nsuccinylalaalaprophepnitroanlilid
sucaapfpna
purchas
sigma
st
loui
missouri
usa
sucaapfpna
dissolv
tetrahydrofuran
contain
mmoll
licl
stock
solut
concentr
mmoll
dissolv
mmoll
hcl
contain
mmoll
cacl
stock
solut
concentr
mmoll
assay
buffer
mmoll
hepe
mmoll
nacl
ph
final
concentr
mmoll
hepe
mmoll
nacl
deioniz
water
cypd
nmoll
stock
solut
compound
final
concentr
rang
nmoll
preequilibr
h
ice
immedi
assay
start
chymotrypsin
solut
ad
absorb
read
nm
record
peptid
substrat
ad
cm
path
length
cuvett
solut
mix
rapidli
data
collect
hitachi
spectrophotomet
rat
liver
mitochondri
swell
ca
uptakereleas
inhibit
assay
mitochondri
swell
ca
uptakereleas
inhibit
assay
carri
accord
publish
method
mitochondria
isol
differenti
centrifug
liver
adult
wistar
rat
g
overnight
starvat
treatment
rat
liver
excis
wash
moll
sucros
fat
connect
tissu
remov
liver
homogen
wv
use
buffer
mmoll
mannitol
mmoll
edta
mmoll
hepe
bovin
serum
albumin
ph
ice
homogen
centrifug
min
biofug
strato
centrifug
hereu
compani
hanau
germani
sediment
discard
supernat
centrifug
min
twice
collect
supernat
centrifug
min
pellet
mitochondri
fraction
resuspend
test
buffer
mmoll
mannitol
mmoll
sucros
mmoll
hepe
ph
total
mitochondri
protein
determin
use
lowri
assay
use
bovin
serum
albumin
standard
rat
mitochondria
ad
test
buffer
yield
final
concentr
mg
protein
per
ml
test
compound
mix
mitochondria
h
cacl
ad
mitochondri
swell
determin
monitor
absorb
nm
use
hitachi
spectrophotomet
mitochondri
ca
uptakereleas
assay
monitor
use
hitachi
fluoresc
spectrophotomet
describ
previous
molecular
model
dock
cypd
sequenc
rattu
norvegicu
retriev
genbank
genbank
protein
id
http
wwwncbinlmnihgov
clustal
w
program
use
carri
sequenc
align
sequenc
cypd
rattu
norvegicu
human
cypa
sequenc
similar
ident
cypd
cypa
posit
make
protein
data
bank
pdb
human
cypa
ideal
templat
cypd
model
build
model
trpr
gener
base
pdb
templat
retriev
protein
databas
use
model
program
encod
insight
ii
model
use
spatial
restraint
method
build
protein
model
structur
templat
protein
use
deriv
spatial
restraint
express
probabl
densiti
function
restrain
featur
model
structur
lowest
violat
score
lowest
energi
score
chosen
candid
refin
routin
homolog
modul
insight
ii
use
adjust
posit
side
chain
final
structur
model
optim
use
amber
forc
field
follow
paramet
distancedepend
dielectr
constant
nonbond
cutoff
kollmanallatom
charg
structur
first
minim
steepest
descent
conjug
gradient
method
energi
gradient
rootmeansquar
sever
structur
analysi
softwar
packag
use
check
structur
qualiti
prostat
modul
insight
ii
use
analyz
bond
angl
torsion
program
use
check
structur
sequenc
compat
structur
compound
construct
scratch
sybyl
optim
energi
converg
tripo
forc
field
charg
major
residu
possibl
compris
bind
site
cypd
identifi
sequenc
align
human
cypa
siteid
program
encod
sybyl
surfac
structur
bind
pocket
construct
use
molcad
modul
sybyl
dock
suit
program
design
find
possibl
orient
ligand
receptor
site
orient
ligand
evalu
shapescor
function
andor
function
approxim
ligandreceptor
bind
energi
shapescor
function
empir
function
resembl
van
der
waal
attract
energi
ligandreceptor
bind
energi
taken
approxim
sum
van
der
waal
electrostat
interact
energi
initi
orient
score
evalu
gridbas
rigid
bodi
minim
carri
ligand
locat
nearest
local
energi
minimum
within
receptor
bind
site
posit
conform
dock
molecul
optim
use
singl
anchor
search
torsion
minim
method
dock
thirti
conform
per
ligand
build
cycl
maximum
anchor
orient
use
anchorfirst
dock
algorithm
dock
configur
energi
minim
use
maximum
iter
one
minim
cycl
synthesi
compound
gener
compound
synthes
outlin
scheme
order
perform
kinet
analys
bind
cypd
cypa
biacor
instrument
base
surfac
plasmon
reson
spr
technolog
use
typic
exampl
biacor
sensorgram
bind
immobil
cypd
shown
figur
langmuir
bind
fit
model
use
determin
equilibrium
dissoci
constant
k
associ
k
dissoci
k
rate
constant
use
equat
r
repres
respons
unit
c
concentr
analyt
obtain
result
evalu
analysi
kinet
paramet
list
tabl
biacor
result
show
test
compound
exhibit
strong
bind
affin
cypd
k
valu
approxim
due
high
structur
homolog
cypd
cypa
test
compound
high
bind
affin
cypa
indic
tabl
howev
compound
exhibit
higher
bind
specif
cypd
cypa
verifi
intrins
fluoresc
titrat
analysi
cyclophilin
ppias
activ
inhibit
assay
shown
tabl
structur
r
group
compound
scheme
might
play
import
role
ligand
bind
select
cypd
cypa
addit
k
valu
obtain
biacor
assay
agre
appar
equilibrium
dissoci
constant
k
intrins
fluoresc
titrat
analysi
ic
valu
cyclophilin
ppias
activ
inhibit
determin
shown
tabl
agreement
huber
et
al
suggest
biacor
power
use
method
screen
cyclophilin
inhibitor
intrins
fluoresc
titrat
analysi
compound
bind
cypd
bind
site
cypd
cypa
tryptophan
residu
trp
cypd
trp
cypa
investig
bind
affin
test
compound
cypd
cypa
use
intrins
fluoresc
titrat
techniqu
assay
ratio
cypd
bind
compound
use
base
publish
inform
cypacsa
interact
result
molecular
dock
analys
appar
equilibrium
dissoci
constant
k
use
evalu
cypd
bind
affin
test
compound
calcul
accord
method
literatur
assum
occup
cypd
cypa
set
fraction
fluoresc
chang
fc
point
concentr
bound
ligand
equal
bound
protein
half
total
concentr
protein
accordingli
k
equal
total
ligand
concentr
minu
concentr
bound
protein
fc
figur
show
typic
tryptophan
fluoresc
quench
cypd
induc
titrat
test
compound
increas
concentr
sinc
none
compound
show
intrins
fluoresc
absorpt
possibl
effect
experi
could
discount
data
shown
k
valu
summar
tabl
obvious
bind
select
cypd
cypa
could
also
determin
k
valu
compar
k
valu
determin
biacor
assay
cypa
belong
ppias
famili
classic
spectrophotometr
method
use
determin
ppias
inhibit
activ
cypd
cypa
assay
rate
constant
cistran
interconvers
evalu
fit
data
integr
firstord
rate
equat
nonlinear
leastsquar
analysi
typic
exampl
figur
show
cypd
ppias
inhibit
result
increas
concentr
compound
tabl
show
ic
valu
cypd
cypa
fact
ic
valu
accord
well
biacor
fluoresc
titrat
result
tabl
confirm
reliabl
three
detect
approach
rat
ca
depend
mitochondri
swell
ca
uptakereleas
inhibit
assay
gener
mpt
pore
open
mitochondria
encount
abnorm
high
concentr
exogen
ca
ion
pore
allow
solut
da
size
across
inner
mitochondri
membran
lead
mitochondri
swell
swell
detect
time
scan
absorb
nm
extent
swell
proport
fluoresc
quit
low
without
bind
ca
control
high
mitochondri
membran
potenti
prevent
releas
endogen
mitochondri
ca
exogen
ca
ad
fluoresc
increas
immedi
decreas
rapidli
ca
ion
taken
mitochondria
subsequ
accumul
cation
mitochondria
led
mitochondri
swell
depolar
ca
ion
releas
mitochondria
consequ
onset
mpt
indic
increas
fluoresc
ca
releas
complet
block
csa
fluoresc
also
reveal
compound
inhibit
uptakereleas
exogen
ad
ca
certain
extent
figur
show
result
rat
mitochondri
swell
inhibit
assay
csa
control
figur
give
result
mitochondri
ca
uptakereleas
inhibit
assay
result
show
inhibit
abil
compound
ca
uptakereleas
good
agreement
inhibit
abil
mitochondri
swell
found
compound
strong
abil
wherea
inhibit
activ
could
r
group
compar
tail
ethoxycarbonyl
might
prevent
transfer
mitochondria
membran
caus
loss
inhibit
abil
unclear
reason
behavior
cypd
mitochondria
much
complic
purifi
cypd
protein
differ
r
group
might
caus
differ
result
csa
highest
inhibit
activ
rel
gener
inhibit
abil
compound
sequenc
seem
consist
cypd
ppias
inhibit
abil
compound
tabl
result
thu
confirm
fact
cypd
inhibitor
may
possess
possibl
inhibit
activ
ca
depend
mpt
pore
open
molecular
dock
analys
gain
insight
cypd
inhibitor
interact
model
atom
level
dock
analysi
base
molecular
model
carri
without
publish
rat
cypd
crystal
data
rat
cypd
model
talli
well
human
cypd
crystal
pdb
id
structur
shown
figur
weight
root
mean
squar
distanc
ident
score
similar
structur
compound
share
precursor
overlap
structur
element
common
figur
similar
cypa
bind
pocket
cypd
also
fairli
larg
shallow
compos
residu
csa
bind
bind
site
cypd
unlik
case
full
occup
csa
occupi
part
bind
pocket
might
swing
pocket
helekar
patrick
even
demonstr
cypa
key
determin
ppias
activ
compound
show
hydrophob
contact
cypd
cypa
therefor
ppias
activ
cypd
could
inhibit
hydrophob
interact
inhibitor
addit
form
stack
interact
cypd
cypa
tryptophan
residu
cypd
cypa
contribut
chang
fluoresc
intens
data
shown
conclus
work
report
small
quinoxalin
deriv
novel
cypd
inhibitor
vitro
assay
indic
compound
inhibit
ca
depend
rat
liver
mitochondri
swell
ca
uptak
releas
use
spr
fluoresc
titrat
techniqu
kinet
analysi
cypdinhibitor
interact
quantit
perform
measur
ic
valu
test
compound
good
agreement
spr
fluoresc
titrat
result
suggest
power
method
identifi
cypd
inhibitor
studi
indic
bind
select
cypd
cypa
summari
present
work
use
appropri
power
approach
identifi
cypd
inhibitor
develop
small
compound
show
specif
ligandbind
abil
cypd
could
use
inhibit
mpt
pore
open
